| Pacritinib studied in …STUDIED_INderived36 of 36show fewer |
|---|
| → studied in | NCT06303193Phase 1/Phase 2 · recruiting Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms · 36 trials list this drug (16 active) | — | — | Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04282187Phase 2 · recruiting Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms · 36 trials list this drug (16 active) | — | — | Myelodysplastic Syndrome,Myelodysplastic/Myeloproliferative Neoplasm,Myeloproliferative Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06782373Phase 2 · active not recruiting A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) · 36 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07226713Phase 2 · recruiting Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors · 36 trials list this drug (16 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06052618Phase 2 · recruiting Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) · 36 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07148947Phase 2 · recruiting Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms · 36 trials list this drug (16 active) | — | — | Accelerated Phase Myeloproliferative Neoplasm,Blast Phase Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07033598Phase 2 · recruiting Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia · 36 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07387354Phase 1/Phase 2 · withdrawn Pacritinib With Aza for Upfront Myelodysplastic Syndrome · 36 trials list this drug (16 active) | — | — | Myelodysplastic Syndrome,Myelodysplastic Syndrome, Unclassifiable,Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06159491Phase 1/Phase 2 · recruiting Pacritinib in CMML · 36 trials list this drug (16 active) | — | — | Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06675123Phase 1 · recruiting Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma · 36 trials list this drug (16 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679334Phase 1 · not yet recruiting Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms · 36 trials list this drug (16 active) | — | — | Myeloproliferative Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07394153Phase 2 · recruiting Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia · 36 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858256Phase 2 · recruiting Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms · 36 trials list this drug (16 active) | — | — | T-Cell and NK-Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06986174Phase 2 · recruiting A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia · 36 trials list this drug (16 active) | — | — | Indolent Non-Hodgkin Lymphoma,Lymphoplasmacytic Lymphoma,Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635059Phase 2 · terminated Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer · 36 trials list this drug (16 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04520269Phase 1/Phase 2 · active not recruiting A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) · 36 trials list this drug (16 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404361Phase 2 · terminated PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer · 36 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218628Phase 1 · recruiting Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition · 36 trials list this drug (16 active) | — | — | Chronic Myelomonocytic Leukemia,Essential Thrombocythemia,Polycythemia Vera+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03645824Phase 2 · active not recruiting Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) · 36 trials list this drug (16 active) | — | — | Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02055781Phase 3 · terminated Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia · 36 trials list this drug (16 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase,Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01620216Phase 2 · terminated Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia · 36 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03601819Phase 1 · terminated Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders · 36 trials list this drug (16 active) | — | — | Lymphoma,Chronic Lymphocytic Leukemia,Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01773187Phase 3 · terminated Pacritinib Versus Best Available Therapy to Treat Myelofibrosis · 36 trials list this drug (16 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase,Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02323607Phase 1 · completed Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations · 36 trials list this drug (16 active) | — | — | Secondary Acute Myeloid Leukemia,Acute Myeloid Leukemia Post Cytotoxic Therapy,Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02410551Phase 2 · terminated Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) · 36 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02469415Phase 2 · terminated Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) · 36 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02532010Phase 2 · terminated Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML · 36 trials list this drug (16 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02342353Phase 1 · terminated Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) · 36 trials list this drug (16 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02677948Phase 1/Phase 2 · withdrawn Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · 36 trials list this drug (16 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02564536Phase 1 · withdrawn Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) · 36 trials list this drug (16 active) | — | — | Juvenile Myelomonocytic Leukemia,Myelodysplastic Syndrome,Myeloproliferative Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02277093Phase 2 · terminated Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer · 36 trials list this drug (16 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01436084Phase 2 · terminated SB1518 for Patients With Myelodysplastic Syndrome (MDS) · 36 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00719836Phase 1/Phase 2 · completed A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies · 36 trials list this drug (16 active) | — | — | Myelodysplastic Syndrome,Myeloid Leukemia,Acute Myeloid Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00741871Phase 1 · completed A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies · 36 trials list this drug (16 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00745550Phase 1/Phase 2 · completed A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis · 36 trials list this drug (16 active) | — | — | Myeloproliferative Neoplasm,Essential Thrombocythemia,Polycythemia Vera+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01263899Phase 2 · completed A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies · 36 trials list this drug (16 active) | — | — | Hodgkin Lymphoma,Indolent Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |